BMS-986504 for Cancer

This trial tests a new drug, BMS-986504, for individuals with advanced solid tumors that have a specific gene deletion called MTAP. Researchers aim to determine if BMS-986504, an experimental treatment, is safe and effective when used alone or with other cancer treatments. Individuals with a confirmed diagnosis of this cancer type who have not responded to standard treatments might be suitable candidates. Those with a measurable tumor and no active brain metastases may qualify for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering a chance to benefit from a potentially effective new therapy.

The trial information does not specify if you need to stop taking your current medications. However, it does mention that participants should not have prior treatment with certain inhibitors and must be stable without certain medications for brain metastases. It's best to discuss your specific medications with the trial team.

Research has shown that BMS-986504, whether used alone or with other treatments, is generally safe. In earlier studies, participants tolerated BMS-986504 well, with most side effects being mild or moderate. For those using BMS-986504 with Pumitamig and chemotherapy, the safety was manageable, and no new safety issues emerged.

When combined with a Pan-RAS inhibitor, BMS-986504 effectively fought tumors and was well-tolerated. The combination of BMS-986504 with Nivolumab and Relatlimab showed a safety profile consistent with expectations for these treatments. Lastly, using BMS-986504 with Temozolomide and radiotherapy improved treatment effects and quality of life, with manageable side effects.

Researchers are excited about the treatment BMS-986504 for cancer because it offers a unique approach compared to standard therapies like chemotherapy and targeted therapies. Unlike traditional treatments, which often attack cancer cells non-selectively, BMS-986504 is being tested in combination with specific agents like Pumitamig and Pan-RAS inhibitors. This combination targets cancer growth pathways more precisely, potentially reducing harmful side effects. Additionally, some arms of the trial are exploring the combination of BMS-986504 with immunotherapy agents like Nivolumab and Relatlimab, which could enhance the body's immune response to cancer. These innovative combinations might lead to more effective and personalized treatment options for patients with challenging cancer types.

Research has shown promising results for the treatments tested in this trial. Participants in Part 2: Cohort 1 will receive BMS-986504 combined with pumitamig and chemotherapy. Studies indicate that more than half of the patients experienced tumor shrinkage, with a 61.5% response rate in some cancer types. In Part 2: Cohorts 2a, 2b, and 2c, participants will receive BMS-986504 with a Pan-RAS inhibitor, with or without chemotherapy, showing a 29% response rate in certain patients and strong anti-tumor effects in early lab studies. Part 2: Cohort 3 involves BMS-986504 with nivolumab and relatlimab, which showed positive results in treating melanoma, a type of skin cancer. Lastly, participants in Part 2: Cohort 4 will receive BMS-986504 combined with temozolomide and radiotherapy, which improved survival rates in brain cancer trials. Overall, these findings are encouraging for treating cancers with specific genetic traits.²⁶⁷⁸⁹